The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Neoplasm Grading

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about Neoplasm Grading.
Olatoyosi Odenike
Connection Strength
0.031
Neoplasm Grading
  1. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 02; 31(2):393-402.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.